An Evolving Role for AXL in Metastatic Renal Cell Carcinoma

Andrew W. Hahn; Daniel J. George; Neeraj Agarwal

doi:10.1158/1078-0432.CCR-21-3029

An Evolving Role for AXL in Metastatic Renal Cell Carcinoma

Andrew W. Hahn, Daniel J. George, Neeraj Agarwal

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

High tumoral expression of AXL was associated with inferior response to anti-PD-1 therapy and increased tumoral programmed death ligand 1 (PD-L1) expression in patients with metastatic renal cell carcinoma, with particularly poor outcomes in those with high AXL and PD-L1. AXL expression has potential as a biomarker and therapeutic target.

Original language	English (US)
Pages (from-to)	6619-6621
Number of pages	3
Journal	Clinical Cancer Research
Volume	27
Issue number	24
DOIs	https://doi.org/10.1158/1078-0432.CCR-21-3029
State	Published - Dec 15 2021
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-21-3029

Cite this

@article{9b963154494d498783b90a289dc2dadd,

title = "An Evolving Role for AXL in Metastatic Renal Cell Carcinoma",

abstract = "High tumoral expression of AXL was associated with inferior response to anti-PD-1 therapy and increased tumoral programmed death ligand 1 (PD-L1) expression in patients with metastatic renal cell carcinoma, with particularly poor outcomes in those with high AXL and PD-L1. AXL expression has potential as a biomarker and therapeutic target.",

author = "Hahn, {Andrew W.} and George, {Daniel J.} and Neeraj Agarwal",

note = "Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research.",

year = "2021",

month = dec,

day = "15",

doi = "10.1158/1078-0432.CCR-21-3029",

language = "English (US)",

volume = "27",

pages = "6619--6621",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "24",

}

TY - JOUR

T1 - An Evolving Role for AXL in Metastatic Renal Cell Carcinoma

AU - Hahn, Andrew W.

AU - George, Daniel J.

AU - Agarwal, Neeraj

PY - 2021/12/15

Y1 - 2021/12/15

N2 - High tumoral expression of AXL was associated with inferior response to anti-PD-1 therapy and increased tumoral programmed death ligand 1 (PD-L1) expression in patients with metastatic renal cell carcinoma, with particularly poor outcomes in those with high AXL and PD-L1. AXL expression has potential as a biomarker and therapeutic target.

AB - High tumoral expression of AXL was associated with inferior response to anti-PD-1 therapy and increased tumoral programmed death ligand 1 (PD-L1) expression in patients with metastatic renal cell carcinoma, with particularly poor outcomes in those with high AXL and PD-L1. AXL expression has potential as a biomarker and therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=85122379585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122379585&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-21-3029

DO - 10.1158/1078-0432.CCR-21-3029

M3 - Article

C2 - 34598944

AN - SCOPUS:85122379585

SN - 1078-0432

VL - 27

SP - 6619

EP - 6621

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 24

ER -

An Evolving Role for AXL in Metastatic Renal Cell Carcinoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this